

AUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED JUNE 30, 2022 AND THE SIX-MONTH PERIOD ENDED JUNE 30, 2021

CMT RESEARCH FOUNDATION, INC. INDEX TO FINANCIAL STATEMENTS JUNE 30, 2022 AND 2021

	PAGE
INDEPENDENT AUDITOR'S REPORT	
STATEMENTS OF FINANCIAL POSITION	1
STATEMENTS OF ACTIVITIES AND NET ASSETS	2
STATEMENTS OF FUNCTIONAL EXPENSES	3
STATEMENTS OF CASH FLOWS	4
NOTES TO FINANCIAL STATEMENTS	5-9



INDEPENDENT AUDITOR'S REPORT

To the Board of Directors CMT Research Foundation, Inc. Atlanta, Georgia

We have audited the accompanying financial statements of CMT Research Foundation, Inc. (a nonprofit organization), which comprise the statements of financial position as of June 30, 2022 and 2021, and the related statements of activities and net assets, functional expenses and cash flows for the year ended June 30, 2022 and the six-month period ended June 30, 2021, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of CMT Research Foundation, Inc. as of June 30, 2022 and 2021, and the changes in its net assets and its cash flows for the periods then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of CMT Research Foundation, Inc. and to meet our ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about CMT Research Foundation, Inc.'s ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with generally accepted

auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of CMT Research Foundation, Inc.'s internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about CMT Research Foundation, Inc.'s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

goves and Kell

July 31, 2023

CMT RESEARCH FOUNDATION, INC. STATEMENTS OF FINANCIAL POSITION JUNE 30, 2022 AND 2021

ASSETS

		2022	2021			
CURRENT ASSETS		_		_		
Cash and equivalents	\$	3,403,410	\$	1,797,180		
Contributions receivable		301,704		325,215		
Prepaid expenses		10,585				
Total current assets		3,715,699		2,122,395		
LONG-TERM ASSETS						
Contributions receivable		200,000		-		
Total assets	\$	3,915,699	\$	2,122,395		
<u>LIABILITIE</u>	S AND NET AS	SSETS				
CURRENT LIABILITIES						
Accounts payable	\$	72,656	\$	34,486		
Deferred revenue		2,400				
Total current liabilities		75,056		34,486		
Total liabilities		75,056		34,486		
NET ASSETS						
Without donor restrictions		379,298		1,208,040		
With donor restrictions		3,461,345		879,869		
Total net assets		3,840,643		2,087,909		
Total liabilities and net assets	\$	3,915,699	\$	2,122,395		

CMT RESEARCH FOUNDATION, INC. STATEMENTS OF ACTIVITIES AND NET ASSETS FOR THE YEAR ENDED JUNE 30, 2022 AND THE SIX-MONTH PERIOD ENDED JUNE 30, 2021

Year Ended June 30, 2022 Six-Month Period Ended June 30, 2021 **Without Donor** With Donor Without Donor With Donor **Restrictions Total** Restrictions **Total** Restrictions Restrictions REVENUES AND SUPPORT 4.223,460 Contributions \$ 646,354 3,577,106 128,428 \$ 85,000 213,428 156,050 156,050 Special event revenue Less direct cost of special event (84,984)(84,984)Convention revenue 54,632 54,632 3,470 3,470 Interest income 3,127 3,127 106 106 Total revenues and support 775,179 3,577,106 4,352,285 132,004 217,004 85,000 NET ASSETS RELEASED FROM RESTRICTIONS (995,630)995,630 666,548 (666,548)**EXPENSES** Program services 1,757,537 1,757,537 573,723 573,723 Management and general 165,888 74,104 74,104 165,888 **Fundraising** 676,126 676,126 206,741 206,741 Total expenses 2,599,551 2,599,551 854,568 854,568 **CHANGE IN NET ASSETS** (828,742)1,752,734 (56,016)2,581,476 (581,548)(637,564)NET ASSETS Beginning of year 1,208,040 879,869 2,087,909 1,264,056 1,461,417 2,725,473 End of year 379,298 3,461,345 2,087,909 3,840,643 1,208,040 879,869

CMT RESEARCH FOUNDATION, INC. STATEMENTS OF FUNCTIONAL EXPENSES FOR THE YEAR ENDED JUNE 30, 2022 AND THE SIX-MONTH PERIOD ENDED JUNE 30, 2021

Year Ended June 30, 2022 Six-Month Period Ended June 30, 2021 Management Management and General Fundraising **Program Total** and General Fundraising **Total Program** Project expenses \$1,051,922 \$ 1,051,922 343,485 343,485 Compensation 566,483 71,254 272,815 910,552 202,708 23,750 104,468 330,926 Meetings 41,323 1,524 202,654 245,501 5,000 826 5,826 Professional fees 61,826 59,991 44,714 166,531 19,573 33,529 29,550 82,652 Marketing 5,146 2,124 130,209 137,479 175 61,764 61,939 3,810 6,251 Office 11,467 21,611 36,888 695 9,996 16,942 3,412 941 80 1,021 Travel 13,132 8,643 25,187 Miscellaneous 711 1,027 57 13,895 1,312 15,918 2,262 3,346 9,573 9,573 8,431 8,431 Insurance

Total

<u>\$1,757,537</u> <u>\$ 165,888</u> <u>\$ 676,126</u> <u>\$2,599,551</u> <u>\$ 573,723</u> <u>\$ 74,104</u> <u>\$ 206,741</u> <u>\$ 854,568</u>

CMT RESEARCH FOUNDATION, INC. STATEMENTS OF CASH FLOWS FOR THE YEAR ENDED JUNE 30, 2022 AND THE SIX-MONTH PERIOD ENDED JUNE 30, 2021

		ear Ended ine 30, 2022	Six-Month Period Ended June 30, 2021			
	Ju	ine 30, 2022	Jul	16 30, 2021		
CASH FLOWS FROM OPERATING ACTIVITIES						
Contributions received	\$	4,049,371	\$	813,428		
Interest income received		3,127		106		
Other income received		125,698		3,470		
Project expenses		(1,033,174)		(318,758)		
Compensation expenses		(913,786)		(327,692)		
Marketing expenses		(120,349)		(63,654)		
Meeting expenses		(256,086)		-		
Professional fees expense		(166,531)		(85,222)		
Travel expenses		(25,187)		(1,021)		
Other operating expenses		(56,853)		(29,545)		
Net cash provided by (used in)						
operating activities		1,606,230		(8,888)		
NET INCREASE (DECREASE) IN CASH						
AND CASH EQUIVALENTS		1,606,230		(8,888)		
CASH AND EQUIVALENTS, Beginning of period		1,797,180		1,806,068		
CASH AND EQUIVALENTS, End of period	\$	3,403,410	\$	1,797,180		

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. CMT Research Foundation, Inc. (the "Organization") was founded in 2018 with a mission dedicated to delivering treatments and cures for Charcot-Marie-Tooth ("CMT") disease. CMT is a genetic nerve disease with over 100 known genetic causes. Onset can be at birth or later in life and is characterized by degeneration of motor nerves which can lead to severe disability or death. The primary function of the Organization is to strategically partner with academia and industry stakeholders who are pursuing a cure or more effective treatment for CMT.

Effective January 1, 2021, the Organization changed its fiscal year end from December 31 to June 30.

- B. The accompanying financial statements have been prepared on the accrual basis in conformity with accounting principles generally accepted in the United States of America.
- C. The Organization classifies net assets and revenues, expenses, gains and losses based on the existence or absence of donor-imposed restrictions. The Organization records contributions of cash and other assets as net assets without donor restrictions unless specifically restricted by the donor. All other restricted contributions are recorded as an increase in net assets with donor restrictions. When restrictions expire (that is, when a stipulated time restriction ends or purpose restriction is accomplished), net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the Statements of Activities and Net Assets as "net assets released from restrictions." Accordingly, net assets of the Organization and changes therein are classified and reported as follows:

<u>Net assets without donor restrictions</u> - Net assets that are not subject to donor-imposed stipulations and are, therefore, available for the general operation of the Organization.

Net assets with donor restrictions - Net assets that are subject to donor-imposed restrictions. Some donor-imposed restrictions may be temporary in nature; for example, restrictions that may or will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions may be perpetual in nature; for example, stipulating those resources be maintained in perpetuity. The donors of these assets generally permit the Organization to use all of the income earned on related investments for general or specific purposes. More specifically, items included in net assets with donor restrictions are contributions for which restrictions have not been met.

D. The Organization considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. At times, the Organization's cash balances may be in excess of the federally insured limits. However, given the strength of the financial institution, management believes such excess deposits do not create significant loss exposure.

- E. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.
- F. Contributions are recognized as revenue when the donor makes a promise to give that is, in substance, unconditional. Unconditional pledges are recorded at their net realizable value if due within one year. Unconditional pledges expected to be collected in future years are recorded at the present value of their estimated future cash flows. Discounts are calculated using interest rates applicable to the years in which the promise is received. During the periods ended June 30, 2022 and 2021, no discount was recorded as the interest rates were not significant. At June 30, 2022, contributions receivable due more than one year from the Statement of Financial Position date were \$200,000. An allowance for uncollectible contributions receivable is provided based upon management's judgment, considering such factors as prior collection history, type of contribution, relationship with donor and other relevant factors. At June 30, 2022 and 2021, management believes all contributions receivable are fully collectible. Therefore, no allowance for uncollectible accounts is recorded in the accompanying financial statements.

The Organization recognizes revenues from convention ticket sales and fundraising events in the period the event occurs. Amounts received prior to the event are reported as deferred revenue. At June 30, 2022, the Organization had deferred convention revenue of \$2,400. The Organization had no deferred revenue at June 30, 2021.

- G. The accompanying financial statements report certain categories of expenses that are attributable to one or more functions of the Organization, which are defined as program services, management and general, and fundraising. Therefore, these expenses require allocation on a reasonable basis that is consistently applied. Salaries and benefits are allocated on the basis of estimates of time and effort. The remainder of the expenses are primarily allocated through specific identification to the functional expense category due to the nature of the expense.
- H. The Organization is a nonprofit corporation which has been granted tax-exempt status as a public charity under Section 501(c)(3) of the Internal Revenue Code ("IRC"). However, it is subject to IRC Section 511(a) for income taxes on unrelated business income. The Organization had no tax liability as of June 30, 2022 and 2021.
- I. Subsequent events have been evaluated by management through July 31, 2023, the date these financial statements were available to be issued.

2. LIQUIDITY

Financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the Statement of Financial Position date, comprise the following as of June 30, 2022 and 2021:

	2022	2021
Financial assets, at year end Less those unavailable for general expenditures	\$ 3,915,699	\$ 2,122,395
within one year due to: Purpose restrictions by donors Time restrictions by donor	(2,959,641) (501,704)	(879,869)
Total financial assets available to meet cash needs for general expenditure within one year	\$ 454,354	\$ 1,242,526

The Organization has a policy to structure its financial assets to be available as its general expenditures, liabilities and other obligations become due.

3. RESTRICTIONS ON NET ASSETS

Net assets with donor restrictions as of and for the year ended June 30, 2022 are summarized as follows:

Restriction	Jun	e 30, 2021	30, 2021 Contributions		Releases		June 30, 2022	
Subject to specified purpose:								
CMT1A	\$	493,951	\$	3,054,038	\$	(588,348)	\$	2,959,641
CMT2E		40,726		-		(40,726)		-
CMT1B		315,704		-		(315,704)		-
CMTX		24,488		10,500		(34,988)		-
CMT2A		5,000		10,864		(15,864)		-
Subject to specified time:								
Years 2022 - 2023		-		501,704		-		501,704
Total	\$	879,869	\$	3,577,106	\$	(995,630)	\$	3,461,345

Net assets with donor restrictions as of and for the six-month period ended June 30, 2021 are summarized as follows:

Restriction	De	cember 31, 2020	Con	tributions]	Releases	Jun	ne 30, 2021
Subject to specified purpose:								
CMT1A	\$	518,582	\$	80,000	\$	(104,631)	\$	493,951
CMT2E		65,726		-		(25,000)	·	40,726
CMT1B		352,009		-		(36,305)		315,704
CMTX		25,100		-		(612)		24,488
CMT2A		-		5,000		-		5,000
Subject to specified time:								
Years 2021 - 2022		500,000				(500,000)		
Total	\$	1,461,417	\$	85,000	\$	(666,548)	\$	879,869

4. **CONCENTRATIONS**

During the year ended June 30, 2022 and the six-month period ended June 30, 2021, three donors and one donor accounted for approximately 41% and 35% of revenues and support, respectively. Three donors and one donor accounted for approximately 86% and 85% of contributions receivable at June 30, 2022 and 2021, respectively.

5. RETIREMENT PLAN

The Organization adopted a 401(k) safe harbor plan ("the Plan") as of April 15, 2020. Under the Plan, all full-time employees who are at least 21 years of age are eligible to make salary deferrals to the Plan after two months of service. The Plan allows for pre-tax 401(k) deferrals and Roth 401(k) deferrals.

6. COMMITMENTS

The Organization has entered funding arrangements with future payments totaling approximately \$1,348,000 for various research and development projects to develop a cure or treatment for CMT. The agreements contain various terms and conditions to reduce the risk to the Organization. Most agreements include multiple phases or milestones that must be achieved for the Organization to be obligated to make payment. Additionally, the agreements include various repayment terms, royalty payments or equity investment upon development of a successful commercial product.

7. LEGAL SETTLEMENT

In March 2021, Charcot-Marie-Tooth Association ("CMTA") filed a suit against the Organization and an officer seeking unspecified damages and making various claims regarding the officer's previous employment with CMTA and its donor lists. In September 2021, CMTA dismissed the lawsuit in its entirety without prejudice. The Organization's legal costs were covered by insurance, so no donor funds were directed away from essential research to find treatments and/or a cure for CMT.